NCT01390415已完成不适用
A Retrospective Survey to Evaluate the Renoprotective Effect of Losartan in Type II Diabetic Patients With Microalbuminuria and Hypertension in Real Life
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 136
- 主要终点
- Number of Participants With Macroalbuminuria After 6 Months of Treatment
研究概览
简要总结
This study will evaluate whether losartan protects the kidney in hypertensive Type II diabetic participants with microalbuminuria.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 20 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diabetes mellitus
- •Hypertension and has received losartan 50 mg or losartan 100 mg for at least 6 months
- •Microalbuminuria (defined as microalbuminuria > 30 mg/g and < 300 mg/g by spot urine test)
- •Serum creatinine ≤1.5 mg/dL for men and ≤1.4mg/dL for women
- •Urinalysis with white blood cells (WBC) <5 cells per high power field
- •Results of hemoglobin A1c (HbA1c), fasting blood glucose, serum creatinine, urine albumin/urine creatinine ratio and urinary analysis tests at baseline and 6 months after initiating the losartan therapy are available
- •Medical history and co-morbidities (if available) listed in medical records
- •Prescription information of antihypertensive regimen of losartan 50 mg or 100 mg available
- •Exclusion criteria:
- •Treated with angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARB) before initiated treatment with losartan 50 mg or losartan 100 mg
- •Enrollment in another clinical trial
排除标准
- 未提供
结局指标
主要结局
Number of Participants With Macroalbuminuria After 6 Months of Treatment
时间窗: Baseline and Month 6
Macroalbuminuria was defined as having an albumin/creatinine ratio (ACR) \>300 mg/g and ≥30% increase from baseline.
次要结局
- Systolic Blood Pressure (SBP)(Baseline and Month 6)
- Diastolic Blood Pressure (DBP)(Baseline and Month 6)
研究者
相似试验
已完成
3 期
Irbesartan in Type 2 DiabetesMicroalbuminuriaHypertensionType 2 DiabetesNCT00317915Steno Diabetes Center Copenhagen
已完成
1 期
Study to Assess the Optimal Renoprotective Dose of Aliskiren in Hypertensive Patients With Type 2 Diabetes and Incipient or Overt NephropathyDiabetes Mellitus, Type 2NCT00464776Novartis26
已完成
4 期
Spironolactone in Diabetic NephropathyDiabetic NephropathyNCT00317954Steno Diabetes Center Copenhagen48
进行中（未招募）
1 期
This study aims to investigate the potential beneficial effects on the kidney of a new medication called Dapagliflozin in type 2 diabetic patients.Diabetic NephropathyEUCTR2013-004042-42-GBKing’s College London40
已完成
不适用
Evaluation of renoprotective and hypotensive effects by combined use of irbesartan and amlodipine besilate in elderly patients with hypertension.HypertensionJPRN-UMIN000008841Kanazawa Medical University30